Inhibition of Rac controls NPM-ALK-dependent lymphoma development and dissemination

Blood Cancer Journal

Volumn 1, Issue 6, 2011, Pages

  Colomba, A ^a   Giuriato, S ^b   Dejean, E ^b   Thornber, K ^a   Delsol, G ^b   Tronchere H ^a   Meggetto, F ^b   Payrastre, B ^a   Gaits Iacovoni, F ^a  

^a Université de Toulouse   (France)

^b CANCER RESEARCH CENTER OF TOULOUSE   (France)

Author keywords

Anaplastic lymphomas; Dissemination; NPM ALK; Rac1 GTPase

Indexed keywords

4 AMINO 6 [2 [[4 (DIETHYLAMINO) 1 METHYLBUTYL]AMINO] 6 METHYL 4 PYRIMIDINYL] 2 METHYLQUINOLINE; GUANOSINE TRIPHOSPHATASE; MITOGEN ACTIVATED PROTEIN KINASE 3; NUCLEOPHOSMIN ANAPLASTIC LYMPHOMA KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; RAC1 PROTEIN; RAC2 PROTEIN; SYNAPTOPHYSIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENICITY; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LARGE CELL LYMPHOMA; LYMPHOMA; METASTASIS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

EID: 84864039513     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2011.19     Document Type: Article

References (26)

1. Lamant L, Meggetto F, al Saati T, Brugieres L, de Paillerets BB, Dastugue N et al. High incidence of the t(2;5)(p23;q35) translocation in anaplastic large cell lymphoma and its lack of detection in Hodgkin's disease. Comparison of cytogenetic analysis, reverse transcriptase-polymerase chain reaction, and P-80 immunostaining. Blood 1996; 87: 284-291.
2. Turner SD, Alexander DR. What have we learnt from mouse models of NPM-ALK-induced lymphomagenesis? Leukemia 2005; 20: 572-582.
3. Delsol G, Lamant L, Mariamé B, Pulford K, Dastugue N, Brousset P et al. A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2;5 translocation. Blood 1997; 89: 1483-1490. (Pubitemid 27097438)
4. Röttgers S, Gombert M, Teigler-Schelgel A, Busch K, Gamerdinger U, Slany R et al. ALK fusion genes in children with atypical myeloproliferative leukemia. Leukemia 2010; 24: 1197-1245.
5. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 2008; 8: 11-23.
6. Cussac D, Pichereaux C, Colomba A, Capilla F, Pont F, Gaits-Iacovoni F et al. Proteomic analysis of anaplastic lymphoma cell lines: identification of potential tumour markers. Proteomics 2006; 6: 3210-3222. (Pubitemid 43806416)
7. Crockett DK, Lin Z, Elenitoba-Johnson KS, Lim MS. Identification of NPM-ALK interacting proteins by tandem mass spectrometry. Oncogene 2004; 23: 2617-2629. (Pubitemid 38586315)
8. Ambrogio C, Voena C, Manazza AD, Piva R, Riera L, Barberis L et al. p130Cas mediates the transforming properties of the anaplastic lymphoma kinase. Blood 2005; 106: 3907-3916. (Pubitemid 41739031)
9. Colomba A, Courilleau D, Ramel D, Billadeau DD, Espinos E, Delsol G et al. Activation of Rac1 and the exchange factor Vav3 are involved in NPM-ALK signaling in anaplastic large cell lymphomas. Oncogene 2008; 27: 2728-2736. (Pubitemid 351581459)
10. Armstrong F, Duplantier MM, Trempat P, Hieblot C, Lamant L, Espinos E et al. Differential effects of X-ALK fusion proteins on proliferation, transformation, and invasion properties of NIH3T3 cells. Oncogene 2004; 23: 6071-6082. (Pubitemid 39178860)
11. Amin HM, Lai R. Pathobiology of ALK+ anaplastic large-cell lymphoma. Blood 2007; 110: 2259-2267. (Pubitemid 47523143)
12. Cussac D, Greenland C, Roche S, Bai RY, Duyster J, Morris SW et al. Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity. Blood 2004; 103: 1464-1471. (Pubitemid 38168663)
13. Ambrogio C, Voena C, Manazza AD, Martinengo C, Costa C, Kirchhausen T et al. The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation. Cancer Res 2008; 68: 8899-8907.
14. Hall A. Rho GTPases and the control of cell behaviour. Biochem Soc Trans 2005; 33 (part 5): 891-895. (Pubitemid 41659073)
15. Sahai E, Marshall CJ. RHO-GTPases and cancer. Nat Rev Cancer 2002; 2: 133-142.
16. Heasman SJ, Ridley AJ. Mammalian Rho GTPases: new insights into their functions from in vivo studies. Nat Rev Mol Cell Biol 2008; 9: 690-701.
17. Lagarrigue F, Dupuis-Coronas S, Ramel D, Delsol G, Tronchère H, Payrastre B et al. Matrix metalloproteinase-9 is upregulated in nucleophosmin-anaplastic lymphoma kinase-positive anaplastic lymphomas ans activated at the cell surface by the chaperone heat shock protein 90 to promote cell invasion. Cancer Res 2010; 70: 6978-6987.
18. Giuriato S, Foisseau M, Dejean E, Felsher DW, Al Saati T, Demur C et al. Conditional TPM3-ALK and NPM-ALK transgenic mice develop reversible ALK-positive early B-cell lymphoma/leukemia. Blood 2010; 115: 4061-4070.
19. Lamant L, Espinos E, Duplantier M, Dastugue N, Robert A, Allouche M et al. Establishment of a novel anaplastic large-cell lymphoma-cell line (COST) from a 'small-cell variant' of ALCL. Leukemia 2004; 18: 1693-1698. (Pubitemid 39386349)
20. Gao Y, Dickerson JB, Guo F, Zheng J, Zheng Y. Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. Proc Natl Acad Sci USA 2004; 101: 7618-7623. (Pubitemid 38658078)
21. Cantrell DA. GTPases and T cell activation. Immunol Rev 2003; 192: 122-130. (Pubitemid 36613328)
22. Rudiger T, Geissinger E, Muller-Hermelink HK. Normal counterparts of nodal peripheral T-cell lymphoma. Hematol Oncol 2006; 24: 175-180. (Pubitemid 46032890)
23. Thomas EK, Cancelas JA, Chae H-D, Cox AD, Keller PJ, Perrotti D et al. Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease. Cancer Cell 2007; 12: 467-478. (Pubitemid 350046406)
24. Chiarle R, Simmons WJ, Cai H, Dhall G, Zamo A, Raz R et al. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med 2005; 11: 623-629. (Pubitemid 40868302)
25. Li R, Morris SW. Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy. Med Res Rev 2008; 28: 372-412. (Pubitemid 351590540)
26. Choi Y-L, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010; 363: 1734-1739.